Sen. Ted Cruz Demands Answers From The FDA For Limiting Monoclonal Antibody Treatments
WASHINGTON, D.C. – U.S. Sen. Ted Cruz (R-Texas) today sent a letter to the U.S. Food and Drug Administration (FDA) demanding answers after the agency decided to limit the use of monoclonal antibody treatments this week.
In the letter, the Senator asks:
- Identify who specifically decided to limit the use of these monoclonal antibodies to treat COVID-19.
- What was the reason for limiting the use of these monoclonal antibodies’ treatments on January 24th, 2022 allegedly due to Omicron, when the first confirmed U.S. case of Omicron was on December 1, 2021?
- Is there a possibility of a new COVID-19 variants emerging? If so, why would the FDA limit access to these treatments now when they could be highly effective against other future-emerging variants?
Senator Cruz also issued a statement berating the Biden administration following the decision by the FDA earlier this week. “The Biden administration’s track record on COVID is a disgrace. They’ve consistently politicized health and medicine, denying Texans and Americans live-saving treatments. After months of rationing critical antibody therapies, they now entirely pulled the approvals,” the Senator Stated on Tuesday. “Enough is enough. It’s time for the FDA and the Biden administration to put the interests of patients first and to stop politicizing COVID.”
###
